Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis.

Migliori GB, Centis R, D'Ambrosio L, Silva DR, Rendon A.

J Bras Pneumol. 2019 Apr 25;45(2):e20180420. doi: 10.1590/1806-3713/e20180420. English, Portuguese.

2.

Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.

Migliori GB, Nardell E, Yedilbayev A, D'Ambrosio L, Centis R, Tadolini M, van den Boom M, Ehsani S, Sotgiu G, Dara M.

Eur Respir J. 2019 Jun 5;53(6). pii: 1900391. doi: 10.1183/13993003.00391-2019. Print 2019 Jun.

PMID:
31023852
3.

Recent evidence on delamanid use for rifampicin-resistant tuberculosis.

Pontali E, Centis R, D'Ambrosio L, Toscanini F, Migliori GB.

J Thorac Dis. 2019 Mar;11(Suppl 3):S457-S460. doi: 10.21037/jtd.2018.11.26. No abstract available.

4.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

5.

Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae.

Visca D, Zampogna E, Sotgiu G, Centis R, Saderi L, D'Ambrosio L, Pegoraro V, Pignatti P, Muňoz-Torrico M, Migliori GB, Spanevello A.

Eur Respir J. 2019 Mar 14;53(3). pii: 1802184. doi: 10.1183/13993003.02184-2018. Print 2019 Mar. No abstract available.

PMID:
30872556
6.

Delamanid: does it have a role in tuberculosis treatment?

Centis R, Sotgiu G, Migliori GB.

Lancet Respir Med. 2019 Mar;7(3):193-195. doi: 10.1016/S2213-2600(18)30455-7. Epub 2019 Jan 7. No abstract available.

PMID:
30630779
7.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
8.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.

PMID:
30096332
9.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

PMID:
29903862
10.

Tuberculosis elimination: where are we now?

Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho ACC, Centis R, D'Ambrosio L, Visca D, Spanevello A, Battista Migliori G.

Eur Respir Rev. 2018 Jun 13;27(148). pii: 180035. doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30. Review.

11.

Eliminating tuberculosis in Latin America: making it the point.

Duarte R, Silva DR, Rendon A, Alves TG, Rabahi MF, Centis R, Kritski A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):73-76. doi: 10.1590/s1806-37562017000000449. English, Portuguese. No abstract available.

12.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
13.

Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.

Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702267. doi: 10.1183/13993003.02267-2017. Print 2018 Mar. No abstract available.

PMID:
29567721
14.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

PMID:
29567720
15.

Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.

Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477. Review.

PMID:
29470252
16.

Point of care diagnostics for tuberculosis.

García-Basteiro AL, DiNardo A, Saavedra B, Silva DR, Palmero D, Gegia M, Migliori GB, Duarte R, Mambuque E, Centis R, Cuevas LE, Izco S, Theron G.

Pulmonology. 2018 Mar - Apr;24(2):73-85. doi: 10.1016/j.rppnen.2017.12.002. Epub 2018 Feb 14. Review.

17.

Diagnostic performances of the Xpert MTB/RIF in Brazil.

Silva DR, Sotgiu G, D'Ambrosio L, Pereira GR, Barbosa MS, Dias NJD, Saderi L, Centis R, Migliori GB.

Respir Med. 2018 Jan;134:12-15. doi: 10.1016/j.rmed.2017.11.012. Epub 2017 Nov 21.

PMID:
29413498
18.

Tuberculosis elimination: a dream or a reality? The case of Oman.

Al Yaquobi F, Al-Abri S, Al-Abri B, Al-Abaidani I, Al-Jardani A, D'Ambrosio L, Centis R, Matteelli A, Manissero D, Migliori GB.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702027. doi: 10.1183/13993003.02027-2017. Print 2018 Jan. No abstract available.

PMID:
29326321
19.

Migration, TB control and elimination: Whom to screen and treat.

Rendon A, Centis R, Zellweger JP, Solovic I, Torres-Duque CA, Robalo Cordeiro C, de Queiroz Mello FC, Manissero D, Sotgiu G.

Pulmonology. 2018 Mar - Apr;24(2):99-105. doi: 10.1016/j.rppnen.2017.11.007. Epub 2017 Dec 29. Review.

20.

Tuberculosis, social determinants and co-morbidities (including HIV).

Duarte R, Lönnroth K, Carvalho C, Lima F, Carvalho ACC, Muñoz-Torrico M, Centis R.

Pulmonology. 2018 Mar - Apr;24(2):115-119. doi: 10.1016/j.rppnen.2017.11.003. Epub 2017 Dec 21. Review.

21.

Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Amicosante M, D'Ambrosio L, Munoz M, Mello FCQ, Tebruegge M, Chegou NN, Seghrouchni F, Centis R, Goletti D, Bothamley G, Migliori GB; TB Diagnostic Survey Working Group.

J Bras Pneumol. 2017 Sep-Oct;43(5):380-392. doi: 10.1590/S1806-37562017000000219. English, Portuguese.

22.

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. No abstract available.

23.

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?

Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Int J Infect Dis. 2017 Dec;65:133-134. doi: 10.1016/j.ijid.2017.10.019. Epub 2017 Nov 6. No abstract available.

24.

Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.

Luzzati R, Migliori GB, Zignol M, Cirillo DM, Maschio M, Tominz R, Ventura G, Patussi V, D'Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Busetti M, Di Santolo M, Raviglione M, Confalonieri M.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701414. doi: 10.1183/13993003.01414-2017. Print 2017 Nov. No abstract available.

25.

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB.

J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16. Review.

26.

Understanding the multidrug-resistant tuberculosis epidemic in China.

Centis R, D'Ambrosio L, Migliori GB.

Int J Tuberc Lung Dis. 2017 Sep 1;21(9):955. doi: 10.5588/ijtld.17.0438. No abstract available.

PMID:
28826442
27.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

28.

A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium.

D'Ambrosio L, Tadolini M, Centis R, Chalmers JD, Migliori GB.

Indian J Med Res. 2017 Mar;145(3):261-263. doi: 10.4103/ijmr.IJMR_37_17. No abstract available.

29.

Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences.

Dara M, Sulis G, Centis R, D'Ambrosio L, de Vries G, Douglas P, Garcia D, Jansen N, Zuroweste E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):727-736. doi: 10.5588/ijtld.16.0940.

PMID:
28633696
30.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

31.

Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Arakaki Sanchez D, Dockhorn F, Centis R, Migliori GB.

Eur Respir J. 2017 Apr 12;49(4). pii: 1602309. doi: 10.1183/13993003.02309-2016. Print 2017 Apr. No abstract available.

32.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
33.

World TB Day 2017: Strengthening the fight against TB.

Solovic I, Centis R, D'Ambrosio L, Visca D, Battista Migliori G.

Presse Med. 2017 Mar;46(2 Pt 2):e1-e4. doi: 10.1016/j.lpm.2017.02.002. No abstract available.

PMID:
28336002
34.

Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.

Pontali E, D'Ambrosio L, Centis R, Sotgiu G, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1700146. doi: 10.1183/13993003.00146-2017. Print 2017 Mar. No abstract available.

35.

Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Galesi VM, Barreira D, Sanchez DA, Dockhorn F, Centis R, Caminero JA, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602445. doi: 10.1183/13993003.02445-2016. Print 2017 Mar.

36.

The challenge of the new tuberculosis drugs.

Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB.

Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Review. French.

PMID:
28256383
37.

Breaking the barriers: Migrants and tuberculosis.

Sotgiu G, Dara M, Centis R, Matteelli A, Solovic I, Gratziou C, Rendon A, Battista Migliori G.

Presse Med. 2017 Mar;46(2 Pt 2):e5-e11. doi: 10.1016/j.lpm.2017.01.013. Epub 2017 Feb 28. Review.

PMID:
28256381
38.

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.

Int J Mol Sci. 2017 Feb 7;18(2). pii: E341. doi: 10.3390/ijms18020341. Review.

39.

Management of extensively drug-resistant tuberculosis.

Centis R, Sotgiu G, Migliori GB.

Lancet Respir Med. 2017 Apr;5(4):237-239. doi: 10.1016/S2213-2600(16)30437-4. Epub 2017 Jan 19. No abstract available.

PMID:
28109868
40.

Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.

Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, Torres-Cruz A, Flores-Vergara H, Martínez-Mendoza D, García-Sancho C, Centis R, Salazar-Lezama MÁ, Pérez-Padilla R.

Arch Bronconeumol. 2017 May;53(5):245-250. doi: 10.1016/j.arbres.2016.10.021. Epub 2017 Jan 11. English, Spanish.

41.

Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.

Muñoz-Torrico M, Caminero Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, Torres-Cruz A, Flores-Ergara H, Martínez-Mendoza D, García-Sancho C, Centis R, Salazar-Lezama MÁ, Pérez-Padilla R.

Rev Port Pneumol (2006). 2017 Jan - Feb;23(1):27-30. doi: 10.1016/j.rppnen.2016.11.009. Epub 2016 Dec 31.

42.

Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?

Centis R, D'Ambrosio L, Zumla A, Migliori GB.

Int J Infect Dis. 2017 Mar;56:30-33. doi: 10.1016/j.ijid.2016.11.416. Epub 2016 Dec 1.

43.

Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe.

Matteelli A, Centis R, Sulis G, Tadolini M.

Travel Med Infect Dis. 2016 Nov - Dec;14(6):588-590. doi: 10.1016/j.tmaid.2016.11.017. Epub 2016 Nov 30.

PMID:
27913312
44.

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Rendon A, Tiberi S, Scardigli A, D'Ambrosio L, Centis R, Caminero JA, Migliori GB.

J Thorac Dis. 2016 Oct;8(10):2666-2671. No abstract available.

45.

European policies in the management of tuberculosis among migrants.

D'Ambrosio L, Centis R, Dara M, Solovic I, Sulis G, Zumla A, Migliori GB.

Int J Infect Dis. 2017 Mar;56:85-89. doi: 10.1016/j.ijid.2016.11.002. Epub 2016 Nov 9.

46.

WHO recommendations for multidrug-resistant tuberculosis - Authors' reply.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Zumla A, Migliori GB.

Lancet. 2016 Nov 5;388(10057):2234-2235. doi: 10.1016/S0140-6736(16)31465-9. No abstract available.

PMID:
27825499
47.

Classifying new anti-tuberculosis drugs: rationale and future perspectives.

Tiberi S, Scardigli A, Centis R, D'Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ, Spanevello A, Visca D, Zumla A, Migliori GB, Caminero Luna JA.

Int J Infect Dis. 2017 Mar;56:181-184. doi: 10.1016/j.ijid.2016.10.026. Epub 2016 Nov 3.

48.

Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.

Sotgiu G, Tiberi S, Centis R, D'Ambrosio L, Fuentes Z, Zumla A, Migliori GB.

Int J Infect Dis. 2017 Mar;56:190-193. doi: 10.1016/j.ijid.2016.10.021. Epub 2016 Nov 2.

49.

Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?

Muñoz-Torrico M, Rendon A, Centis R, D'Ambrosio L, Fuentes Z, Torres-Duque C, Mello F, Dalcolmo M, Pérez-Padilla R, Spanevello A, Migliori GB.

J Bras Pneumol. 2016 Sep-Oct;42(5):374-385. doi: 10.1590/S1806-37562016000000226. Review. English, Portuguese.

50.

Recent developments in the diagnosis and management of tuberculosis.

Sulis G, Centis R, Sotgiu G, D'Ambrosio L, Pontali E, Spanevello A, Matteelli A, Zumla A, Migliori GB.

NPJ Prim Care Respir Med. 2016 Nov 3;26:16078. doi: 10.1038/npjpcrm.2016.78. Review.

Supplemental Content

Loading ...
Support Center